LPs choose Europe

Charles River Laboratories International Inc. (NYSE:CRL) and Knight Therapeutics Inc. (TSX:GUD) invested in Forbion Capital Partner's third life sciences fund to gain access to the firm's largely European portfolio.

Forbion Capital Fund III (FCF III) closed this month at €183 million ($208.2 million). About 70% of FCF III will target European investments, with the rest earmarked for the U.S. and Canada. ...